Core Viewpoint - CollPlant Biotechnologies is expanding its distribution channels for its Vergenix™ STR product in Europe and Asia, targeting the treatment of tendon injuries through innovative rhCollagen technology [1][3]. Group 1: Product Overview - VergenixSTR is designed for treating tendinopathy, promoting healing and repair of various tendon injuries, including tennis elbow and Achilles tendonitis [1][2]. - The product combines cross-linked rhCollagen with Platelet-rich plasma (PRP), facilitating a controlled release of growth factors to enhance healing [4]. Group 2: Distribution Expansion - CollPlant has signed distribution agreements for VergenixSTR with companies in the Netherlands, Turkey, and India, aiming to sell in the Benelux region, Spain, and Turkey [1][2]. - The new distributor for Benelux and Spain specializes in medical device sales focused on orthopedics, with the first shipment made in February 2025 [2]. Group 3: Market Potential - The CEO of CollPlant expressed optimism about the market potential for VergenixSTR as the company expands its distribution network in Europe and Asia-Pacific [3]. - The company plans to take further steps in 2025 to broaden its distribution reach for VergenixSTR [3].
CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia